Literature DB >> 1541381

Insulin binding to trophoblast plasma membranes and placental glycogen content in well-controlled gestational diabetic women treated with diet or insulin, in well-controlled overt diabetic patients and in healthy control subjects.

G Desoye1, H H Hofmann, P A Weiss.   

Abstract

Insulin binding to trophoblast plasma membranes and the placental glycogen content were measured in twelve healthy women, in eleven well-controlled gestational diabetic women who were treated either with diet alone (n = 4) or with insulin (n = 7) and in 18 women with well-controlled overt diabetes mellitus (six White B; four White C; eight White D). The competitive binding assay was carried out with 22 concentrations of unlabelled insulin. Binding data were analysed by a non-linear direct model fitting procedure assuming one non-cooperative binding site. Maximum specific binding was unchanged in the total collective of gestational diabetic women, but was decreased by 30% in those treated with diet (6.2 +/- 2.2%) and increased by 90% in insulin-treated women (16.4 +/- 10.2%) as compared to the control subjects (8.7 +/- 2.5%). The diet-treated women had only 40% as many and those treated with insulin had more than twice as many receptors compared to control subjects on a per mg protein basis and if expressed per total placenta. In patients with overt diabetes mellitus maximum specific binding (18.5 +/- 10.6%) was higher (p less than 0.05) due to more receptors compared to control subjects but was similar to the insulin-treated gestational diabetic patients. Maximum specific binding and receptor concentrations did not correlate linearly with maternal plasma insulin levels. Receptor affinities were virtually similar in all groups (1.8 x 10(9) l/mol). The placental glycogen content was reduced (p less than 0.05) to about 80% of that of control subjects in the diet-treated collective, whereas it was unchanged compared to control subjects in the insulin-treated gestational diabetic women despite a 40% increase (p less than 0.001) of the maternal-to-cord serum glucose ratio. In overt diabetic patients the maternal-to-cord serum glucose ratio and the placental glycogen content were higher (p less than 0.05) than in the control subjects. We conclude that trophoblast plasma membranes from gestational diabetic women treated with diet alone express less and those from women treated with insulin express more insulin receptors than those from a healthy control group in vitro. These differences could not have been disclosed without consideration of the mode of treatment. Trophoblast plasma membranes from overt diabetic women have more insulin receptors than those from healthy control subjects.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1541381     DOI: 10.1007/bf00400851

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  47 in total

1.  Measurement of non-specific binding by parallel or consecutive incubation procedures in receptor homogenates following tissue disintegrations by sonification.

Authors:  G Desoye
Journal:  J Biochem Biophys Methods       Date:  1990-06

2.  Disruption of solid tissue for plasma membrane preparation.

Authors:  D Snary; F R Woods; M J Crumpton
Journal:  Anal Biochem       Date:  1976-08       Impact factor: 3.365

3.  Human placental insulin binding in normal and well-controlled diabetic patients.

Authors:  D M Nelson; J Ortman-Nabi; E M Curran
Journal:  Gynecol Obstet Invest       Date:  1990       Impact factor: 2.031

4.  Glucose uptake, utilization, and transfer by the human placenta as functions of maternal glucose concentration.

Authors:  S Hauguel; V Desmaizieres; J C Challier
Journal:  Pediatr Res       Date:  1986-03       Impact factor: 3.756

5.  The effect of insulin on glucose metabolism of the incubated human placenta.

Authors:  A J Szabo; R D Grimaldi
Journal:  Am J Obstet Gynecol       Date:  1970-01-01       Impact factor: 8.661

6.  Binding of insulin to solubilized insulin receptor from human placenta. Evidence for a single class of noninteracting binding sites.

Authors:  R A Kohanski; M D Lane
Journal:  J Biol Chem       Date:  1983-06-25       Impact factor: 5.157

7.  REgulation of insulin binding to isolated hepatocytes: correction for bound hormone fragments linearizes Scatchard plots.

Authors:  D B Donner
Journal:  Proc Natl Acad Sci U S A       Date:  1980-06       Impact factor: 11.205

8.  Protein kinase-C-induced down-regulation of calcitonin receptors and calcitonin-activated adenylate cyclase in T47D and BEN cells.

Authors:  D M Findlay; V P Michelangeli; P J Robinson
Journal:  Endocrinology       Date:  1989-11       Impact factor: 4.736

9.  Characteristics of the microvillus brush border of human placenta: insulin receptor localization in brush border membranes.

Authors:  J A Whitsett; J L Lessard
Journal:  Endocrinology       Date:  1978-10       Impact factor: 4.736

10.  Gestational diabetes mellitus. Heterogeneity of maternal age, weight, insulin secretion, HLA antigens, and islet cell antibodies and the impact of maternal metabolism on pancreatic B-cell and somatic development in the offspring.

Authors:  N Freinkel; B E Metzger; R L Phelps; S L Dooley; E S Ogata; R M Radvany; A Belton
Journal:  Diabetes       Date:  1985-06       Impact factor: 9.461

View more
  22 in total

1.  Differential regulation of genes for fetoplacental lipid pathways in pregnancy with gestational and type 1 diabetes mellitus.

Authors:  Tatiana Radaelli; Jacques Lepercq; Ali Varastehpour; Subhabrata Basu; Patrick M Catalano; Sylvie Hauguel-De Mouzon
Journal:  Am J Obstet Gynecol       Date:  2009-06-26       Impact factor: 8.661

2.  Insulin control of placental gene expression shifts from mother to foetus over the course of pregnancy.

Authors:  U Hiden; A Maier; M Bilban; N Ghaffari-Tabrizi; C Wadsack; I Lang; G Dohr; G Desoye
Journal:  Diabetologia       Date:  2005-12-13       Impact factor: 10.122

3.  Gestational diabetes mellitus alters apoptotic and inflammatory gene expression of trophobasts from human term placenta.

Authors:  Thomas R Magee; Michael G Ross; Lauren Wedekind; Mina Desai; Siri Kjos; Louiza Belkacemi
Journal:  J Diabetes Complications       Date:  2014-03-24       Impact factor: 2.852

Review 4.  The placenta-brain-axis.

Authors:  Cheryl S Rosenfeld
Journal:  J Neurosci Res       Date:  2020-02-27       Impact factor: 4.164

5.  Sex differences in the association of cord blood insulin with subcutaneous adipose tissue in neonates.

Authors:  M Eder; B Csapo; C Wadsack; J Haas; P M Catalano; G Desoye; M N M van Poppel
Journal:  Int J Obes (Lond)       Date:  2015-09-21       Impact factor: 5.095

6.  Overexpression of GLUT3 placental glucose transporter in diabetic rats.

Authors:  P Boileau; C Mrejen; J Girard; S Hauguel-de Mouzon
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

7.  Increased expression of low-affinity insulin receptor isoform and insulin/insulin-like growth factor-I hybrid receptors in term placenta from insulin-resistant women with gestational hypertension.

Authors:  H Valensise; Y Y Liu; M Federici; D Lauro; D Dell'anna; C Romanini; G Sesti
Journal:  Diabetologia       Date:  1996-08       Impact factor: 10.122

8.  Insulin receptor binding from mid-term and full-term placentas of patients with gestational diabetes mellitus and normal pregnant women.

Authors:  O S al-Attas
Journal:  Mol Cell Biochem       Date:  1995-10-04       Impact factor: 3.396

9.  Altered activity of the system A amino acid transporter in microvillous membrane vesicles from placentas of macrosomic babies born to diabetic women.

Authors:  A G Kuruvilla; S W D'Souza; J D Glazier; D Mahendran; M J Maresh; C P Sibley
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

10.  Insulin receptors in syncytiotrophoblast and fetal endothelium of human placenta. Immunohistochemical evidence for developmental changes in distribution pattern.

Authors:  G Desoye; M Hartmann; A Blaschitz; G Dohr; T Hahn; G Kohnen; P Kaufmann
Journal:  Histochemistry       Date:  1994-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.